BioSpace News Archive

Companies to offer Paige’s machine learning technologies via Leica Biosystems digital pathology platform to offer advanced end-to-end digital pathology workflow solutions

Amendola Communications, a nationally recognized, award-winning healthcare and technology public relations and marketing agency, announced today that infectious disease testing technology leader Alveo Technologies has chosen the firm as its public relations agency to manage thought leadership initiatives, media relations, content marketing and social media.

Direct participation is accelerating discoveries about the causes of autism and the development of targeted treatments and supports

Ultivue announces the addition of Richard C. Malabre, CPA in the role of Chief Financial Officer, as the company adds to its growing executive team.

Battelle Research Scientist and Microbiologist Sydney Corkran is the 2020 recipient of the Dr. Billy Richardson Young NBC Researcher Award.

PerkinElmer, Inc ., a global leader committed to innovating for a healthier world, today announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs

CDISC and the National Organization for Rare Disorders (NORD ® ) have announced a partnership to develop global data standards for rare diseases. The data standards will be released in a Therapeutic Area User Guide that will be available at no cost on the CDISC website for researchers to leverage in studies to maximize data’s full potential.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s first quarter 2021 financial results will be released after market close on Thursday, April 29, 2021.

Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has established its Chemical, Manufacture and Controls (CMC) procedures for the production of THCVHS drug product suitable for Good Laboratory Practice (GLP) non-clinical research.

Vaxess Technologies, Inc., a biotechnology company developing vaccines and therapeutics delivered through a next-generation sustained-release intradermal microneedle patch, announced it was awarded a Commercialization Readiness Program (CRP) grant from the National Institute of Allergy and Infectious Diseases (NIAID grant number SB1AI164584), a part of the U.S. National Institutes of Health (NIH).